Current stock page

Stock Analysis

Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis

Harmony Biosciences Holdings, Inc. (HRMY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

HRMY Stock Analysis Summary

Harmony Biosciences Holdings, Inc. (HRMY) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 89/100. Risk is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

HRMY at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$33.76
AIQ Score73/100
Overall ViewBullish
Technical Analysis ConsensusStrong Sell
Market Cap$1.97B
P/E Ratio (TTM)10.96
Forward P/E—
EPS (Q3 FY2026)$0.83
Revenue (Q3 FY2026)$268.92M
Dividend Yield (TTM)0.00%
Beta0.63
Volume844.9K
52-week range$25.90-$43.49
RSI 1436.41
50-Day SMA$38.65
200-Day SMA$34.57
Analyst Price Target$51.50
Next EarningsFeb 23, 2027
As of Nov 13, 2026 · Market close

HRMYHarmony Biosciences Holdings, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$33.76−$0.04 (−0.12%)

Latest quote

  • Momentum
    66
  • Value
    89
  • Quality
    77
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

HRMY Stock Analysis Summary

Harmony Biosciences Holdings, Inc. (HRMY) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 89/100. Risk resilience is the weakest current factor at 63/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, HRMY has AIQ Score of 73/100 with Value base of 89/100 and fading Risk resilience at 63/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (89/100) leads while Risk resilience (63/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.12% stock move · HRMY classified in Biotechnology.

Current Evidence

BullishHRMY is in a bullish AIQ regime; Value is the strongest visible factor at 89/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is HRMY Bullish or Bearish Right Now?

HRMY currently has a bullish overall setup. Value is the strongest factor at 89/100, while Risk Resilience is weakest at 63/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 77/100.
  • - Momentum is constructive at 66/100.
  • - Analyst target implies +52.55% upside from the latest quote.
Bear Case
  • - Price is -2.35% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (37 vs 1).

Current Consensus

HRMY's Technical Analysis Consensus is currently Strong Sell, with 1 buy, 8 neutral, and 37 sell votes. HRMY's 14-day RSI is 36.41, which places the stock in a weaker momentum range. HRMY's beta is 0.63, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in HRMY?

The largest recent change in HRMY is Momentum moving down by 8.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-3.0
Momentum
-8.0
Quality
+0.0
Risk
+0.0

What Would Change the HRMY Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

HRMY Decision Framework

Public evidence layers, setup checks, and risk context for Harmony Biosciences Holdings, Inc..

Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis

Harmony Biosciences Holdings, Inc. has an AIQ Score of 73/100 in a Bullish regime. Value is strongest at 89/100. Beta is 0.63, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextHRMY is in a Bullish AIQ regime with score 73/100.
Signal ConflictThe primary conflict is that value leads at 89/100 while risk lags at 63/100.
Factor EvidenceMomentum 66/100 · Value 89/100 · Quality 77/100 · Risk 63/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 89/100.

TimingPass

Momentum is 66/100 and RSI (14) is 36.4.

Regime fitPass

HRMY is in a Bullish regime at 73/100.

Risk controlWait

Risk factor is 63/100 with beta 0.63 and annual volatility 40.59%.

ConflictWait

Current conflict: value leads at 89/100 while risk lags at 63/100.

AIQ Score
73/100
Price
$33.76
Beta
0.63
RSI (14)
36.4

HRMY Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

HRMY Fundamentals

HRMY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$268.92M
Net income
$48.2M
Free cash flow
$76.69M
View full HRMY fundamental analysis

HRMY Technical Analysis

HRMY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
36.41
Price vs SMA-50
-12.65%
View full HRMY technical analysis

HRMY Stock Catalysts

Track HRMY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 23, 2027
Analyst target
$51.50
News items
5
View HRMY earnings and stock catalysts

HRMY Dividend Analysis

HRMY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View HRMY dividend history and analysis

HRMY Financial Data

HRMY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$268.92M
EPS
$0.83
Periods
8
View HRMY financials

HRMY Risk Analysis

HRMY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.63
Risk score
63/100
1Y volatility
40.59%
View HRMY risk analysis

HRMY Stock News

HRMY stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read HRMY stock news

HRMY vs Biotechnology Peers

Current peer cohort: HRMY · IDYA · IMNM · IMVT · INBX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
HRMY
Current stock
73/10089/10066/10063/1000.0740.59%Current
IDYA
IDEAYA Biosciences, Inc.
54/10039/10063/10061/1000.1444.94%HRMY vs IDYA
IMNM
Immunome, Inc.
48/100—45/10047/1000.4560.72%HRMY vs IMNM
IMVT
Immunovant, Inc.
52/100—61/10052/1000.958.62%HRMY vs IMVT
INBX
Inhibrx Biosciences Inc.
40/100—50/10040/1000.4982.28%HRMY vs INBX
Pairwise Compare links: IDYA · IMNM · IMVT · INBXHRMY vs IDYAHRMY vs IMNMHRMY vs IMVTHRMY vs INBXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a HRMY stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for HRMY: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
10.96
As of Nov 13, 2026
Revenue growth
12.30%
Gross margin
74.03%
Current debt / equity
0.14
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$268.92M
Quarter net income
$48.2M
Quarter free cash flow
$76.69M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
36.41
MACD
-1.42

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
63/100
Beta
0.63
Annual volatility
40.59%
Max drawdown
-34.49%

HRMY Stock FAQ

What is HRMY stock price today?

Harmony Biosciences Holdings, Inc.'s current stock price is $33.76. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is HRMY bullish or bearish right now?

HRMY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is HRMY's market cap?

HRMY's market cap is $1.97B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is HRMY's current P/E ratio?

HRMY's current P/E ratio is 10.96 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is HRMY's RSI?

HRMY's 14-day RSI is 36.41 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is HRMY above its 50-day and 200-day moving averages?

HRMY is -12.65% from its 50-day SMA and -2.35% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is HRMY's next earnings date?

HRMY's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does HRMY pay a dividend?

HRMY's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.